Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV by Harries, Anthony D et al.
CORRESPONDENCE Open Access
Operational research in malawi: making a
difference with cotrimoxazole preventive therapy
in patients with tuberculosis and HIV
Anthony D Harries
1,2*, Rony Zachariah
3, Rhehab Chimzizi
4, Felix Salaniponi
5, Francis Gausi
6, Henry Kanyerere
6,
Erik J Schouten
7, Andreas Jahn
8,9, Simon D Makombe
8, Frank M Chimbwandira
8 and James Mpunga
6
Abstract
Background: In Malawi, high case fatality rates in patients with tuberculosis, who were also co-infected with HIV,
and high early death rates in people living with HIV during the initiation of antiretroviral treatment (ART) adversely
impacted on treatment outcomes for the national tuberculosis and ART programmes respectively. This article i)
discusses the operational research that was conducted in the country on cotrimoxazole preventive therapy, ii)
outlines the steps that were taken to translate these findings into national policy and practice, iii) shows how the
implementation of cotrimoxazole preventive therapy for both TB patients and HIV-infected patients starting ART
was associated with reduced death rates, and iv) highlights lessons that can be learnt for other settings and
interventions.
Discussion: District and facility-based operational research was undertaken between 1999 and 2005 to assess the
effectiveness of cotrimoxazole preventive therapy in reducing death rates in TB patients and subsequently in
patients starting ART under routine programme conditions. Studies demonstrated significant reductions in case
fatality in HIV-infected TB patients receiving cotrimoxazole and in HIV-infected patients about to start ART.
Following the completion of research, the findings were rapidly disseminated nationally at stakeholder meetings
convened by the Ministry of Health and internationally through conferences and peer-reviewed scientific
publications. The Ministry of Health made policy changes based on the available evidence, following which there
was countrywide distribution of the updated policy and guidelines. Policy was rapidly moved to practice with the
development of monitoring tools, drug procurement and training packages. National programme performance
improved which showed a significant decrease in case fatality rates in TB patients as well as a reduction in early
death in people with HIV starting ART.
Summary: Key lessons for moving this research endeavour through to policy and practice were the importance of
placing operational research within the programme, defining relevant questions, obtaining “buy-in” from national
programme staff at the beginning of projects and having key actors or “policy entrepreneurs” to push forward the
policy-making process. Ultimately, any change in policy and practice has to benefit patients, and the ultimate
judge of success is whether treatment outcomes improve or not.
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Operational research may be defined as the search for
knowledge on strategies, tools or interventions which
leads to improved programme performance and/or
health service delivery [1]. In 1996, the Malawi National
Tuberculosis Control (NTP) Programme embraced the
concept of operational research and started a research
programme that translated directly into several improve-
ments in policy and practice [2,3]. Before this year, TB
control activities had not been going well, quarterly
supervision had declined and funding was an issue. The
Department for International Development, UK, (DFID)
pledged support for TB programme activities, such as
procurement of drug and consumable supplies and rou-
tine quarterly supervision, and for operational research
with the latter activity being used within the programme
to collect data on weaknesses and to implement inter-
ventions to solve the challenges that it faced. This sup-
port by a new donor at that time was welcomed by the
Malawi Ministry of Health.
Between 1996 and 2004, other donors such as the
Norwegian Agency for International Cooperation
(NORAD) and the Royal Netherlands Tuberculosis
Association (KNCV) came on board to support activities
within the Malawi NTP that included operational
research as an integral part of programme activities. For
the research, a partnership was set up whereby research
ideas from within the National TB Programme, from
local institutions (such as the Malawi Medical School,
non-governmental organizations such as Medecins sans
Frontieres and the National AIDS Programme) and
from international organizations (such as the World
Health Organization, The International Union Against
Tuberculosis and Lung Disease and the Liverpool
School of Tropical Medicine) were discussed and
endorsed at the six-weekly meetings of the Malawi TB
Programme Management Group. After priorities were
established, research activities were then implemented
by the various stakeholders, although many were
planned, initiated, completed and published within the
Malawi TB Programme itself.
The guiding principles that under-pinned the research
agenda included i) defining the programme objectives,
ii) identifying constraints that prevented objectives being
met, and iii) asking research questions around those
constraints to try and find solutions that would allow
programme objectives to be achieved. In 2004, when
scale up of antiretroviral therapy (ART) started in
Malawi, operational research based around the same
guiding principles was also used to inform policy and
practice around the delivery of ART.
As an example of how this can work at the national
level for TB and ART programmes and how guiding
principles of operational research are put into practice,
we describe the operational research that was carried
out in Malawi with cotrimoxazole preventive therapy
(CPT), initially in HIV-infected tuberculosis (TB)
patients and then all HIV-infected patients starting
ART. We outline the steps that were taken to translate
these findings into policy and practice, and for both
TB patients and HIV-infected patients starting ART
show how the implementation of CPT made a differ-
ence and reduced death rates. We finally draw on gen-
eral lessons that can be learnt for other settings and
interventions, and suggest that such outcome indictors
of deaths prevented or lives saved are the true measure
of whether operational research in programme settings
is useful or not.
Discussion
Effect of HIV on increasing death rates and reducing cure
rates in the Malawi TB Control Programme
Malawi is a small country in southern Africa with a cur-
rent population of about 13 million. In the 1980s, the
country had one of the first “model” TB control pro-
grammes, a harbinger of the “DOTS” strategy, with
about 4,000 registered cases per annum and cure rates
in new smear-positive pulmonary TB patients at or
higher than 90% [2,3]. These excellent treatment success
rates were not to last. In December 1985, the first AIDS
case was reported in the country, and within ten years
HIV-prevalence in the adult population had soared to
14% [4]. Despite a well functioning NTP, annual case
notifications spiralled out of control to reach 25,000 by
the mid-1990s, which were associated with HIV co-
infection rates of 75% [2,3].
Accompanying the increase in case notifications was a
rapid increase in case fatality, which was reported from
the programme setting and as well as from carefully
monitored cohorts of patients, the case fatality also
being strongly associated with HIV [2,3,5,6]. This had a
major impact on cure rates in new smear-positive PTB
patients which plummeted to their nadir in 1996 at 63%
[2,3]. It became apparent in the mid-1990s that “DOTS”
on its own was insufficient to control the TB epidemic,
and HIV-associated interventions would be required if
death rates were to be reduced.
Need for operational research to assess interventions to
reduce death rates in TB patients
Two randomised controlled trials in Cote d’Ivoire asses-
sing the effect of cotrimoxazole in HIV-infected adults
were published in 1999. The first showed a decrease in
morbidity in HIV-infected adults [7], while the second
conducted in HIV-infected patients with TB showed a
significant reduction in mortality [8]. These studies
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AIDS (UNAIDS) to issue provisional recommendations
in 2000 that all people living with HIV (PLHIV) in
Africa who were symptomatic should receive CPT as
part of a standard package of care [9].
The Cote d’Ivoire trial and the UNAIDS recommenda-
tions had important implications. At the time, there
were three randomised controlled trials on CPT taking
place in Malawi, Senegal and Cape Town, and all of
these were prematurely stopped due to ethical consid-
erations that evidence of efficacy was now established.
However, the Malawi Ministry of Health (MoH) was
reluctant to embark on a national policy of CPT for all
PLHIV because of concerns about differences in com-
monly occurring disease pathogens and cotrimoxazole
resistance rates between West and Central Africa.
Furthermore, there were fears that widespread use of
CPT would encourage cross-resistance to sulphadoxine-
pyrimethamine which, at the time, was the national first
line anti-malarial treatment for Plasmodium falciparum
[10]. The Malawi MoH therefore encouraged and
endorsed district operational research to gather national
evidence to support or refute the use of CPT.
Operational research on offering HIV testing and
cotrimoxazole to TB patients in Malawi and the initial
policy decision
Two district-based operational research studies were
undertaken and completed in Thyolo, the southern
region, and Karonga, the northern region of Malawi
[11,12]. The aim of the two studies was similar, namely
to evaluate the feasibility and effectiveness of a package
of HIV testing and CPT offered to TB patients regis-
tered under routine programme conditions. Mortality
during anti-TB treatment was documented in all TB
patients offered this package and registered during a 12-
month period, and compared with mortality in all TB
patients not offered the package and registered during a
12-month period the year before - namely, “historical
controls”. Active household tracing of patients was
undertaken in both districts to ensure that mortality
data were reliable.
A total of 2,703 TB patients were studied in both
groups and in the two districts. In Thyolo, overall case
fatality significantly declined from 36% in the control
group to 28% in the intervention group, and in Kar-
onga overall case fatality was also significantly reduced
from 37% to 29%. The number of TB patients needing
HIV testing and CPT to prevent one death during the
course of anti-TB treatment was calculated at 12.5 in
each district. In Blantyre district, a further study was
conducted in 579 HIV-infected TB patients comparing
two different doses of CPT and comparing case fatal-
ity rates with those observed in the National TB
cohort and a previous TB cohort in whom a large
majority had been tested for HIV and carefully fol-
lowed to the end of TB treatment [13]. Case fatality
was significantly reduced in patients offered CPT, and
there was no difference in outcomes between patients
offered CPT 480 mg daily and those offered 960 mg
daily.
The results of these district operational research stu-
dies were presented at a large stakeholders’ meeting
convened by the Malawi MoH in October 2002. This
meeting was organised by certain key actors within the
TB Programme - so called “policy entrepreneurs"(see
Table 1) - who ensured that the policy-making process
remained on the agenda and moved forward. Impor-
tant policy decisions were made at the end of that
meeting [14]. The package of HIV testing and CPT
was to be continued in the three districts in TB
patients, and the intervention was to be scaled up to
all TB patients country wide in a phased approach
over three years. This was to be accompanied by
appropriate guidelines, a training package and respon-
sibility for procurement and distribution of CPT stay-
ing in the hands of the Malawi NTP. The uptake of
the intervention was to be carefully monitored along
with treatment outcomes, and further operational
research was to be conducted as necessary to answer
relevant questions arising from the field. As there was
no evidence to support the benefit of HIV testing and
CPT in PLHIV who did not have TB, the intervention
was to be used only for HIV-infected TB patients until
such time as additional evidence of benefit in PLHIV
without TB was available.
Table 1 “Policy entrepreneurs” in the context of the
Malawi National TB Programme
These are senior people within the National TB Programme (TB
Programme Director and National TB Advisor responsible for operational
research), who are well connected with senior personnel in the Ministry
of Health and other actors in the health sector (for example, the
Medical School)
They are responsible for the overall TB operational research programme
and provide direction to the research questions and research
implementation in the field
They assess the outcomes of the research and decide how this may
influence policy within the context of the TB Programme and the wider
health sector: this is discussed within programme management group
meetings
Once decisions are made about the way forward, they assume
responsibility for initial discussions with senior people in the Ministry of
Health (for example, director of preventive services, secretary for health)
They take responsibility for the forthcoming policy meetings, and act as
the secretariat for the organization and chairmanship of the meetings
and for writing the minutes
They take responsibility for drafting new policy, and once this is agreed
for dissemination country wide
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patients, further operational research and impact on TB
programme performance
As a result of the policy decision from the MoH, the
Malawi NTP together with the National AIDS Com-
mission developed a 3-year plan to expand HIV-TB
activities [14]. Soon after this plan was approved in
late 2002, a country-wide situational assessment was
carried out to assess the state of HIV/AIDS and joint
HIV/TB services in hospitals, health centres and clinics
throughout the country and to identify facilities to be
included in the first phase of HIV testing and CPT
implementation. National guidelines were developed
that included how the package was to be administered,
contraindications to CPT, doses for adults and chil-
dren, management of adverse effects, logistics of pro-
viding CPT and finally how to use the new HIV
testing and CPT registers for monitoring and evalua-
tion. These registers were prepared and printed, and
were used alongside TB patient registers. A training
package was developed and a structured plan put in
place to brief and train all TB registration facilities
over a three-year period
CPT scale up started in 2003 at 15 facilities. An early
review of the first 3 months’ activities was carried out
and proved invaluable in identifying challenges and sol-
ving misunderstandings [14]. Further operational
research was also undertaken to answer pertinent ques-
tions. A study in Thyolo district showed that adherence
to CPT in rural areas was excellent based on verbal veri-
fication of drug intake, physical verification of pill count
balance and urine trimethoprim detection by gas chro-
matography and mass spectrometry [15]. Despite good
medication adherence, research also demonstrated a
growing increase of faecal Escherichia coli resistance to
cotrimoxazole in HIV-infected TB patients receiving the
drug, which prompted some concerns about the long
term protective benefits of such chemoprophylaxis [16].
D u r i n gs c a l eu p ,t h eM a l a w iN T Pw a sr e s p o n s i b l ef o r
the administration of CPT during anti-TB treatment,
but once this was completed patients were referred back
to general health services to receive medication. Opera-
tional research documented that the majority of patients
continued receiving CPT from health centres, although
drug stock-outs and transport costs to health centres to
collect drugs lead to interruptions of prophylaxis [17].
Routine data from the Malawi NTP showed that
between 2002 and 2008 there was a significant increase
in HIV testing amongst TB patients with the majority of
HIV-positive patients being started on CPT (Table 2a).
Treatment outcomes in new smear-positive pulmonary
TB patients gradually improved, and by 2008, the global
cure rate target of 85% was reached for the first time in
20 years since the start of the HIV/AIDS epidemic
(Table 2b).
Scale up of antiretroviral therapy and the problem of
early death rates
In 2004, the country embarked on rapid scale up of
antiretroviral therapy (ART), supported financially
through the Global Fund to fight AIDS, TB and malaria
(GFATM) and implemented through a public health
approach based on TB-DOTS principles [18,19]. One of
the major problems encountered in the first years of
ART scale up was high early mortality- defined as
deaths during the first 6 months of treatment. This
Table 2 National Tuberculosis case finding and treatment outcome data in Malawi between 2002 and 2008
2 (a): Case Notifications, HIV testing and Cotrimoxazole Preventive Therapy (CPT)
2002 2003 2004 2005 2006 2007 2008
TB case notifications 27,531 28,234 27,000 27,610 27,105 25,966 25,688
Number HIV tested
(%)
2130
(8%)
3983
(14%)
6681
(25%)
12243
(44%)
17,253
(64%)
21,551
(83%)
21557
(84%)
Number HIV-positive
(%)
1,630
(77%)
2,734
(69%)
4,804
(72%)
8,453
(69%)
12,064
(70%)
15,491 (72%) 13,677 (63%)
Number started CPT
(%)
Not known 2,349
(86%)
4,649
(97%)
8,073
(96%)
11,244
(93%)
13,779 (89%) 13,148 (96%)
2 (b): Treatment outcomes in new smear-positive PTB patients evaluated nationally for outcomes
2002 2003 2004 2005 2006 2007 2008
New smear-positive PTB patients evaluated 7,693 7,603 8,021 7,965 7,955 8065 7632
Treatment success
(%)
5,572
(72%)
5,650
(74%)
6,082
(76%)
6,178
(78%)
6,369
(80%)
6707
(83%)
6534
(86%)
Death
(%)
1,500
(19%)
1,410
(19%)
1,387
(17%)
1,265
(16%)
1,018
(13%)
739
(9%)
574
(7.5%)
Other outcomes
(%)
621
(9%)
543
(7%)
552
(7%)
522
(6%)
568
(7%)
619
(8%)
524
(6.5%)
Legend: other outcomes = default, transfer out, failure. [the data were obtained from annual NTP reports]
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Saharan Africa [19,20]. In the quarterly reports pro-
duced by the HIV Department, a consistent finding was
that two thirds of all patients known to have died on
ART did so in the first three months of treatment. Mea-
sures to reduce early mortality were urgently needed.
Operational research on cotrimoxazole to reduce early
death rates in HIV-infected persons starting antiretroviral
therapy and policy decision
Anecdotal experience suggested that CPT given before
or at the start of ART reduced early death rates, and
operational research was carried out to provide more
evidence for this intervention. Comparisons of 6-month
mortality with data obtained from ART registers and
medical records were made between 6 facilities provid-
ing ART without CPT and 5 facilities providing ART
with CPT [21]. The 6-month mortality rate was signifi-
cantly lower at ART-CPT sites (10.7%) compared with
ART sites alone (18%) [6-month mortality risk reduction
= 41%, p = 0.0013], with survival differences apparent as
early as 40 days after the start of ART. These data were
consistent with subsequent reports from other African
countries demonstrating a synergistic effect of CPT with
ART, especially in the early months of treatment
[22,23]. The Malawi data prompted the HIV Depart-
ment of the MoH, again through “policy entrepreneurs”,
to convene a national stakeholders meeting to re-exam-
ine the use of CPT in PLHIV.
At the national stakeholders meeting in 2005, new evi-
dence on CPT was reviewed, particularly studies that
had been carried out in other sub-Saharan African
countries [24-27], which included the joint WHO/
UNAIDS/UNICEF statement on use of cotrimoxazole as
prophylaxis in HIV-exposed and HIV-infected children
[28]. Evidence showed that CPT was associated with a
25%-46% reduction in mortality in PLHIV in sub-
Saharan Africa, even in areas with high bacterial resis-
tance to the antibiotic. CPT was also associated with
fewer hospitalisations, weight gain, a rise in CD4-lym-
phocyte counts and a decrease in HIV viral loads. Effi-
cacy was maintained over 1-2 years of follow-up. There
were few adverse reactions and high levels of adherence
were documented. In summary, CPT appeared to be a
safe, cheap and readily available anti-microbial agent,
which could extend and improve the quality of life of
PLHIV. The earlier concerns about widespread use of
CPT increasing resistance of Plasmodium falciparum to
sulfadoxine-pyrimethamine were partially allayed by stu-
dies in children in Mali [29].
There was therefore unanimous agreement to modify
the current national recommendations for CPT, and for
Malawi to adopt a policy that CPT be provided free of
charge to adults and children living with HIV/AIDS as
p a r to fam i n i m u mp a c k a g eo fc a r e[ 3 0 ]( s e eT a b l e3 ) .
Malawi’s policy and guidelines were in line with those
subsequently released by WHO in 2006 [31].
From policy to practice: scaling up of cotrimoxazole
preventive therapy for people living with HIV and impact
on early deaths on antiretroviral therapy
Following the adoption of the policy, the HIV depart-
ment of the MoH wrote a circular with guidelines on
CPT drug regimens and individual patient supplies, con-
traindications, duration of therapy, recruitment, follow-
up monitoring and evaluation and drug supply issues.
This circular was distributed country-wide for immedi-
ate use, and national ART guidelines were eventually
updated based on the new evidence [32]. ART treatment
cards were modified to incorporate data on use of CPT.
Pharmacy dispensing registers for CPT in PLHIV who
were not eligible for ART were also developed and
printed to track uptake and usage of CPT, and these
were placed in pharmacies under the responsibility of
pharmacy technicians. A training package was devel-
oped, and the CPT policy and guidelines were incorpo-
rated into the ARV-HIV related diseases management
module that was taught to clinicians and nurses in the
country. The policy was also incorporated into other
Table 3 Policy Guidelines for Cotrimoxazole Preventive
Therapy in Malawi (2005)
In Adults:
Cotrimoxazole should be offered to the following HIV-positive adults
(aged 15 years and above):
￿ All persons with symptomatic HIV disease (WHO Clinical Stage 2,3
and 4)
￿ All persons who have a CD4-lymphocyte count of 500/mm
3 or
less, regardless of symptoms
￿ Pregnant women after the first trimester who are symptomatic or
have a CD4-lymphocyte count < 500/mm
3
Note: In adults there is not enough evidence to recommend cotrimoxazole
to HIV-positive adults who are asymptomatic (i.e., WHO Clinical Stage 1).
However, if evidence is forthcoming in the future to support a change,
then this recommendation will be re-examined. It is also felt that the
threshold of CD4-count of 500 cells/mm
3 may be too high, but it is agreed
to stay with this threshold as it is similar to that recommended by the
World Health Organization. Again, if evidence is forthcoming in the future
that this threshold is too high, the recommendation will be re-examined
In Children:
Cotrimoxazole should be offered to children in the following
circumstances:
￿ Any child, aged 6 weeks or above, born to an HIV-positive
woman irrespective of whether the woman received antiretroviral
therapy in pregnancy
￿ Any child, 6 weeks or more, who is HIV-positive regardless of
symptoms
Note: All HIV-positive children should be offered cotrimoxazole because
they have higher viral loads than adults, progress faster to AIDS and to
death compared with adults and at present do not have the same
opportunities to access antiretroviral therapy as adults
Reference [30]
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ment of Childhood Illness (IMCI). Teachers at the var-
ious training institutions in Malawi for nurses, clinical
officers and medical doctors were made aware of the
policy revisions so that they could incorporate them
into the curriculum for undergraduate teaching of the
management of HIV-related illness. A non-governmental
organization assisted the HIV Department in training
clinical, nursing and pharmacy staff at all district and
mission hospitals in the country, and especially phar-
macy technicians on the use and monitoring of CPT.
National forecasting and procurement of CPT needs
was integrated into the established practices for ARV
drugs. Special packaging of 120 cotrimoxazole tablets
per tin was ordered to facilitate 2-month adult dispen-
sing, and thus removing the previous tiresome burden
on nurses having to count tablets from 1000-tablet tins.
The number of patients receiving CPT is now recorded
every quarter as part of the HIV Department’s quarterly
reports for the country.
As of December 2010, 95% of the 250,987 patients on
ART (including HIV-infected TB patients) were on CPT,
and a cumulative total of 338,609 patients (pre-ART and
ART) had been entered in CPT registers. However, this
underestimates the use of CPTa st h er e g i s t e r sh a dn o t
been used consistently by all sites [33]. Early mortality on
ART has declined considerably. In quarter 2, 2006, 11%
of new patients died within the first three months of
ART initiation [33]. Early mortality has declined to less
than 5% in quarter 4, 2010, according to the routine
records [33]. This may be partly due to CPT and also due
to the decline in the proportion of patients starting ART
in WHO Clinical Stage 4 from 25% in quarter 2, 2005, to
about 10% in quarter 4, 2010 [33].
Lessons learnt
The operational research conducted on HIV testing and
CPT, first to HIV-infected TB patients and then to all
PLHIV, provides some important lessons about how to
successfully integrate operational research into a pro-
gramme setting. The key stages for this were: initial pla-
cement of “operational research” within the programme
setting and ensuring senior persons could act as “policy
entrepreneurs"; developing relevant research questions;
carrying out the research studies; disseminating and
publishing the study findings; translating the study find-
ings into action on the ground; and assessing the impact
o np r o g r a m m ep e r f o r m a n c e .S o m eo ft h ek e yl e s s o n s
learnt, including generic lessons, are illustrated in
Table 4, and are further discussed below.
Contextual placement of operational research within a
programme setting
Right from the start, the operational research pro-
gramme was placed within the Malawi NTP with the
Programme Director strongly supporting and the
National TB Advisor taking responsibility for coordi-
nating the research programme. These two people
were the “policy entrepreneurs” (see Table 1), well
connected to senior people in the Ministry of Health
and to other stakeholders in the health sector such as
the Medical School and non-governmental organiza-
tions. A similar context prevailed in the HIV/AIDS
programme. The small size of the country, the strong
support from the Government Ministry of Health for
this type of work and the close connections with
other key stakeholders in the health sector were
important determinants of the success of the opera-
tional research. Larger countries with different politi-
cal and governance systems may find this more
difficult.
Defining the research questions, getting “buy-in” and using
“policy entrepreneurs”
The importance of defining relevant questions for pro-
gramme and country staff, obtaining “buy-in” from
national programme staff and other interested stake-
holders at the beginning of a project and having the
key actors or “policy entrepreneurs” [34] to push for-
ward the policy-making process cannot be over-
emphasised, and these were probably the most impor-
tant elements of the success of moving this research
endeavour through to policy and practice. Without
this structure, it is likely that the research would have
been published, but without the impact for changing
policy or practice. The research questions that were
asked were priorities for the programme, and were not
set by academic institutions which might have had a
different agenda. Furthermore, the results of the var-
ious studies were of immense interest to the NTP and
to the HIV/AIDS programme, and this ensured that
strong linkages were made in getting the research
findings to policy at the Ministry of Health and to
practice at health facilities in the districts. Important
lessons are that operational research should be
embedded within a programme structure with a focal
point identified, research questions asked from within
the programme and a clear budget line set aside to
support activities.
Disseminating and publishing results
It is important to disseminate and particularly publish
results, as the latter lends credibility to the findings [35].
Operational research, if undertaken, is often not written
up and submitted for scientific publication, and many of
the lessons that could be learnt do not appear in the
public domain [36,37]. At country level, it is crucial to
have a clear roadmap for dissemination through MoH
channels to allow policies to be adopted and the neces-
sary practices that are needed for implementation to be
driven forward on the ground.
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At present, guidelines or a road-map for this process of
moving research into policy and practice do not exist at
national or international level, and the activities that
happen tend to be ad hoc. This should change, and
clear, practical steps for dissemination and influencing
policy and practice need to be made, based on success-
ful experiences such as those illustrated in this paper.
Assessing the impact on programme performance
Ultimately, any change in policy and practice has to
benefit patients and the community, and hence the ulti-
mate judge of success is whether treatment outcomes
improve or not. It is sometimes difficult to ascribe direct
causality in these situations, but that is of secondary
concern to programmes where achievement of perfor-
mance (be it through a direct effect or as an indirect
effect of introducing new interventions) has to be the
ultimate goal.
Summary
￿ In Malawi, high case fatality rates in patients with
tuberculosis (TB), who were also co-infected with
HIV, and high early death rates in people living with
HIV during the initiation of antiretroviral treatment
(ART) adversely impacted on treatment outcomes
for the national TB and ART programmes
respectively.
￿ District and facility-based operational research was
undertaken to assess the effectiveness of cotrimoxa-
zole preventive therapy (CPT) in reducing death
rates in TB patients and subsequently patients start-
ing ART under routine programme conditions. Stu-
dies showed the beneficial effects of CPT in HIV-
infected TB patients and in HIV-infected patients
about to start ART, following which the findings
were rapidly disseminated nationally at stakeholder
meetings convened by the Ministry of Health and
internationally through conferences and peer-
reviewed scientific publications.
￿ The Ministry of Health made policy changes based
on the available evidence, following which there was
countrywide distribution of the updated policy and
guidelines. Policy was rapidly moved to practice with
the development of monitoring tools, drug procure-
ment and training packages. National programme
performance improved, as was demonstrated from
routine data, which showed a significant decrease in
case fatality rates in TB patients as well as a
Table 4 Generic lessons learnt from operational research with cotrimoxazole preventive therapy in Malawi
Malawi-based experience General lessons learnt
There were high case fatality rates of TB patients on anti-TB treatment
alone, and thus a need for HIV-specific interventions
There were high early death rates of people living with HIV starting
antiretroviral treatment
Research questions must be relevant to programme needs.
Operational research leadership and coordination must be placed within
the programme.
Research on cotrimoxazole was endorsed by MoH, and district studies
were designed and implemented in conjunction with national
programme staff
Research should be endorsed and designed with programme MoH staff
in order to increase the probability of findings and recommendations
from the study being accepted and implemented
Research was carried out at district or facility level using routine systems;
data were collected using registers and treatment cards; all patients were
included with no special inclusion and exclusion criteria
Research can and should be effectively carried out within programme
settings and routine health services
Key actors or “policy entrepreneurs” in the programmes helped to move
forward the process of policy making
National meetings were held to engage all stakeholders, to obtain “buy-
in” of the results and to get advice and direction as to how to move
forward
Publication of results in international-peer reviewed journals brought
credibility to findings as a result of the peer-review process, and allowed
dissemination of results internationally
Key actors or “policy entrepreneurs” must be identified and given the
task of moving forward the policy process
When research is completed, dissemination must occur nationally, and if
judged of wider importance then internationally as well
Publication of operational research in peer-reviewed journals adds
credibility to the study findings
Clear policy decisions were obtained from MoH about the study findings,
and directives given about how to implement the new interventions
Research should influence national policy and practice
Policy documents were prepared and widely distributed through
circulars around the country
National Guidelines were updated with new evidence and new policy
Monitoring tools were prepared and disseminated; drug forecasting was
integrated into established processes; training materials were developed
and used at different levels; uptake of new interventions were reported
in national quarterly reports
Programmes need to implement the new policy and practices
Key actors and “policy entrepreneurs within programmes play an
important role in this process
International guidelines or a road-map need to be developed to better
direct the national steps that logically help move research to policy and
practice
There was a clear demonstration of impact in reducing case fatality and
increasing treatment success in TB patients, and in reducing early death
rates in people with HIV starting ART
The ultimate benefit is an impact on programme performance and
treatment outcomes
MoH = Ministry of Health; ART = antiretroviral therapy
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Page 7 of 9reduction in early death rates in people with HIV
starting ART.
￿ Key lessons for moving this research endeavour
through to policy and practice were the importance
of placing operational research within the pro-
gramme setting, defining relevant questions for pro-
gramme and country staff, obtaining “buy-in” from
national programme staff at the beginning of pro-
jects and having key actors or “policy entrepreneurs”
to push forward the policy-making process.
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